~~<i id='B96E98073F'><strike id='B96E98073F'><tt id='B96E98073F'><pre id='B96E98073F'></pre></tt></strike></i>~~

Home» focus» focus

focus

author：knowledge 2025-09-30 04:00:16 Page View：67176

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Death toll from an explosion and collapse of a Paris building in June climbs to 3
Next article： FDA approval of Sarepta Duchenne genetic therapy gives me hope

explore

Anesthesiologist group: stop taking Ozempic before surgery

EspeciallyinthefirstweeksoftakingdrugslikeOzempic,foodstayslongerinthestomach—aprobleminsurgeries.Ad

Review: 'Barbie' will hit you like a shot in the heart

6:22RyanGosling,left,asKenandMargotRobbieasBarbieareseeninastillfromWarnerBros.Pictures'"Barbie."Cou

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

1:19Ademonstratorrunsonthethirdnightofprotestssparkedbythefatalpoliceshootingofa17-year-olddriverint

Artificial intelligence advances fuel industry trying to preserve loved ones after death

3:26Thisillustrationshowsahumanoidrobottouchingtouchingdataonascreen.YuichiroChino/GettyImagesWhenJu